Loading
A phase 1/2 trial of Pyrotinib and Trastuzumab rezetecan in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT06015048 by Jiangsu HengRui Medicine Co., Ltd., with 364 participants planned, started 2023-08-11 and due to reach its primary completion in 2026-11. Interventions recorded: SHR-A1811 combined with Pyrotinib. and SHR-A1811 combined with other antitumor therapies.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pyrotinib, Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Pyrotinib, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.